Femoston Table 1 n / film about 1mg / 10mg 28 pc

Description

Composition
Active substance:
1 tablet contains Femoston® 1: Dydrogesterone 10 mg; Estradiol 1 mg. 1 tablet contains Femoston® 2: Dydrogesterone 10 mg; Estradiol 2 mg.
Product form:
Tablets, film-coated
Packaging 28 tablets.
Contraindications
Pregnancy and lactation; Diagnosed or putative breast cancer; diagnosed or suspected estrogen-dependent malignancies (e.g., endometrial cancer); progestagenzavisimye diagnosed or suspected tumors (e.g., meningiomas); vaginal bleeding of unknown etiology; Untreated endometrial hyperplasia; thrombosis (arterial and venous) and thromboembolism present or in history (including thrombosis, deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic or hemorrhagic cerebrovascular accident); multiple or severe risk factors for arterial and venous thrombosis associated with congenital or acquired predisposition, e.g., lack of protein C, protein deficiency S, deficiency of antithrombin III, the presence of antibodies to phospholipids (antibodies to cardiolipin, lupus anticoagulant), angina pectoris, prolonged immobilization, severe forms of obesity (body mass index greater than 30 kg / m2), cerebrovascular disease or coronary artery, transient ischemic attacks, complicated n expressions valvular atrial fibrillation; acute or chronic liver disease are currently or history (before normalization of liver function tests), including cancers of the liver; porphyria; hypersensitivity to the drug; galactose intolerance, lactase deficiency, malabsorption syndrome glucose-galactose. The drug should be stopped when detecting contraindications and / or under the following conditions: jaundice and / or liver dysfunction; uncontrolled hypertension; It first appeared on the background of HRT migraine headaches.
Precautions: HRT given to women, if the current or a history of them were diagnosed with uterine leiomyomas, endometriosis; presence of risk factors for the occurrence of estrogen-dependent tumors (e.g., relatives first-degree relatives with breast cancer); arterial hypertension; benign tumors of the liver; diabetes, both in the presence of vascular complications, and in their absence; cholelithiasis; migraine or severe headache; systemic lupus erythematosus; endometrial hyperplasia in history; epilepsy; bronchial asthma; otosclerosis.
Dosage
1 mg + 10 mg
Indications
Hormone replacement therapy of disorders caused by estrogen deficiency in menopausal women (no sooner than 6 months after the last menstrual period) or in postmenopausal women; prevention of postmenopausal osteoporosis in women at high risk of fracture in case of intolerance or contraindication to the use of other medications.
Interaction with other drugs
Estrogenic and gestagenic action of the drug Femoston® Femoston® 1 or 2 (depending on the assigned dosing) may be reduced to the following: estrogen metabolism and progestogens may be increased by simultaneous use of drugs, with inducers of microsomal liver enzymes (P450 2B6, 3A4, 3A5, 3A7 ): anticonvulsant (phenobarbital, carbamazepine, phenytoin) and antimicrobials (rifampicin, rifabutin, nevirapine, efavirenz); herbal preparations containing St. John’s wort (Hypericum perforatum), may enhance the metabolism estrogen and progestogen through SYP 450 3A4; ritonavir and nelfinavir, although known as strong inhibitors of CYP 450 3A4, A5, A7, while the use of sex hormones may potentiate their metabolism; amplification of estrogen metabolism and progestogens may clinically manifest reduction effect of the drug and the change in the intensity of bleeding from the vagina. Estrogens may affect the metabolism of other drugs due to competitive binding of enzyme (CYP 450), involved in their cleavage. This should be considered for drugs with narrow breadth of therapeutic action, such as tacrolimus and cyclosporin A (CYP 450 3A4, 3A3), fentanyl (CYP 450 3A4) and theophylline (CYP 450 1A2), since this type of interaction may lead to an increase in concentration in plasma foregoing preparations to a toxic level. In this connection it may require careful monitoring of the intake of drugs over a long period of time, and possibly reducing the dose of tacrolimus, fentanyl, cyclosporin A and theophylline. to study the interaction studies have not been conducted with other drugs *.
* Full details are provided in instructions for medical use agents Femoston® Femoston® 1 or 2 (refer to the dosage depending on the purpose).
Overdose
In case of overdose may develop symptoms such as nausea, vomiting, tension of the mammary glands, dizziness, abdominal pain, drowsiness / fatigue and bleeding “cancel.” Treatment – symptomatic.
pharmachologic effect
Pharmacological properties:
*. Estradiol. Estradiol hemihydrate, a part of the drug Femoston® mini proceeds by dissolving in 17-beta-estradiol, estradiol identical to endogenous human, which is the most active estrogen. Estradiol restores post-menopausal estrogen deficiency in the body in women and reduces the severity of menopausal symptoms. Dydrogesterone. Dydrogesterone – progestogen effective when taken orally, and having a similar parenterally administered progesterone activity. As estrogens promote the proliferation of the endometrium, hormone replacement therapy (HRT), estrogen alone increases the risk of endometrial hyperplasia and cancer. Turning dydrogesterone significantly reduces enlarged under the action of estrogens risk of endometrial hyperplasia in women with a uterus stored. In clinical studies it has been shown that the drug Femoston® mini provides relief of symptoms associated with a lack of estrogen, and bleeding pattern.
* Complete information on the drug is presented in the medical instructions.
Pregnancy and breast-feeding
The drug is contraindicated in pregnancy and during breastfeeding. In the event of pregnancy with drug treatment, therapy should be discontinued immediately *.
* Full details are provided in instructions for medical use agents Femoston® Femoston® 1 or 2 (refer to the dosage depending on the purpose).
Conditions of supply of pharmacies
On prescription.
side effects
Headache, migraine, dizziness; depression, nervousness; abdominal pain, nausea, vomiting, flatulence; voltage / breast tenderness; “Smearing” spotting in postmenopausal metrorrhagia, profuse bleeding menstrualnopodobnoe, scant or no bleeding menstrualnopodobnoe, acyclic bleeding, painful menstrualnopodobnye spotting, abdominal pain, change in vaginal secretion, vaginal candidiasis; back pain (lower back); allergic reactions such as urticaria, skin rashes and itching; asthenic states (weakness, malaise, fatigue), peripheral edema; weight gain *. A list of all side effects represented in the instructions for medical use agents Femoston® Femoston® 1 or 2 (depending on the assigned dosing).
special instructions
Preparation Femoston® Femoston® 1 or 2 (depending on dose) administered only when symptoms, adversely affecting the quality of life. Therapy should be continued for as long as the benefits of the drug outweigh the risks of side effects. Experience with the drug in women older than 65 years is limited. Effect on ability to drive and use machines: Caution should be exercised in the management of vehicles and mechanisms, taking into account the risk of adverse reactions from the part of the nervous system. *
* Full details are provided in instructions for medical use agents Femoston® Femoston® 1 or 2 (refer to the dosage depending on the purpose).
Storage conditions
Store at a temperature not higher than 25 C.
Dosing and Administration
Preparation Femoston® Femoston® 1 or 2 (depending on the assigned dosing) taken orally daily, continuous operation of 1 tablet per day (preferably in one and the same time of day), regardless of the meal. Each package is designed for a 28-day drug. In the first 14 days, take 1 tablet daily of half-arrow package, marked number “1”, and the remaining 14 days -. 1 tablet daily of half-arrow package, marked numeral “2” Treatment should be continued without interruption, immediately after the 28-day cycle should start the next treatment cycle. Usually the treatment should be started with the drug Femoston® 1. Depending on the clinical efficacy, the dosage can be adjusted according to the individual need. If complaints related to estrogen deficiency, stored, the dosage can be increased by using a preparation Femoston® 2. Patients, makes a transition from another continuous sequential or cyclic dosing regime must complete the current cycle and then go to a drug Femoston® 1 or Femoston® 2 (depending on the assigned dosing). Patient, making the transition from a continuous combined regimen may start taking the drug Femoston® Femoston® 1 or 2 (depending on the assigned dosage) on any given day. If the patient skipped a pill, it must be taken within 12 hours after the normal time of reception; otherwise missed tablet should not be accepted, and the next day you need to take a pill at the usual time. Missed doses can increase the likelihood of “breakthrough” uterine bleeding or “spotting” bleeding *.
* Full details are provided in instructions for medical use agents Femoston® Femoston® 1 or 2 (refer to the dosage depending on the purpose).
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist